<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427685</url>
  </required_header>
  <id_info>
    <org_study_id>QATP2687</org_study_id>
    <nct_id>NCT02427685</nct_id>
  </id_info>
  <brief_title>Dysfunctional Hemoglobin CO-ox</brief_title>
  <official_title>Dysfunctional Hemoglobin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nonin Medical, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nonin Medical, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study verifies accuracy of a new pulse co-oximeter in the presence of elevated&#xD;
      carboxyhemoglobin levels.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Carboxyhemoglobin over the range of 0-15 percent as assessed by co-oximetry.</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation accuracy in conditions of elevated carboxyhemoglobin.</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">27</enrollment>
  <condition>Elevated Levels of Carboxyhemoglobin</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pulse Co-Ox</intervention_name>
    <description>Comparison of pulse co-oximeter to blood gas analyzer.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy adult volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is male or female.&#xD;
&#xD;
          -  The subject is of any racial or ethnic group.&#xD;
&#xD;
          -  The subject is between 18 years and 45 years of age.&#xD;
&#xD;
          -  The subject does not have significant medical problems.&#xD;
&#xD;
          -  The subject is willing to provide written informed consent and is willing and able to&#xD;
             comply with study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a BMI greater than 31&#xD;
&#xD;
          -  Has had any relevant injury at the sensor location site&#xD;
&#xD;
          -  Has deformities or abnormalities that may prevent proper application of the device&#xD;
             under test.&#xD;
&#xD;
          -  Has a known respiratory condition.&#xD;
&#xD;
          -  Is currently a smoker.&#xD;
&#xD;
          -  Has a known heart or cardiovascular condition.&#xD;
&#xD;
          -  Is currently pregnant.&#xD;
&#xD;
          -  Is female and actively trying to get pregnant.&#xD;
&#xD;
          -  Has a clotting disorder.&#xD;
&#xD;
          -  Has Raynaud's Disease.&#xD;
&#xD;
          -  Is known to have a hemoglobinopathy such as (anemia, bilirubinemia, sickle-cell&#xD;
             anemia, inherited or congenital methemoglobinemia).&#xD;
&#xD;
          -  The subject has a COHb greater than 3% or MetHb greater than 2%.&#xD;
&#xD;
          -  Has taken blood thinners or medication with aspirin within the last 24 hours.&#xD;
&#xD;
          -  Has unacceptable collateral circulation from the ulnar artery.&#xD;
&#xD;
          -  Has donated more than 300 mL of blood within one month prior to start of study.&#xD;
&#xD;
          -  Is unwilling or unable to provide written informed consent to participate in the&#xD;
             study.&#xD;
&#xD;
          -  Is unwilling or unable to comply with the study procedures for the primary objectives.&#xD;
&#xD;
          -  Has another health condition which in the opinion of the principal investigator makes&#xD;
             him/her unsuitable for testing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip E Bickler, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>April 20, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2015</study_first_posted>
  <last_update_submitted>June 16, 2015</last_update_submitted>
  <last_update_submitted_qc>June 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

